A "DSIR Recognized" Research Based Company
Recognized as Place of research
GeNext Genomics has developed reagent to work on COVID-19 research. Check for the Antigens GNG has for diagnostic and therapeutic.
SARS-CoV-2 is the virus behind the worldwide outbreak of COVID-19 disease. One of the core biological characteristics of SARS-CoV-2 is the presence of spike proteins that enable these viruses to invade host cells and cause infection.
The S protein is an excellent target for vaccine and antiviral research efforts. In addition to it’s role in penetrating cells, S1 protein is a significant inducer for neutralizing antibodies.
GeNext Genomics developed SARS-CoV-2 recombinant proteins such as Spike-S1, RBD etc. The protein could be used in animal immunization, antibody development, etc.